LENZ Therapeutics, Inc. (LENZ) Stock

LENZ Therapeutics, Inc. (LENZ) is a Healthcare stock trading at $6.15 (as of 2026-06-18), with a market capitalization of $243.94M and a trailing P/E of -1.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

LENZ Therapeutics, Inc. is a biopharmaceutical company developing and commercializing vision-related therapies in the United States. Its product candidates, LNZ100 and LNZ101, are in Phase III clinical trials for the treatment of presbyopia, and the company is headquartered in Del Mar, California.

Valuation — source: SEC EDGAR (first-party)
Price	$6.15
Market Cap	$243.94M
P/E Ratio	-1.7
EV / EBITDA	-1.4
Price / Book	0.78
Price / Sales	9.19
DCF Value (model)	$-37.20
DCF Upside vs Price	-704.9%

Profitability & Growth — source: SEC EDGAR
Revenue (TTM)	$19.09M
Net Margin	-430.3%
Return on Equity	-44.2%
Current Ratio	10.40
Revenue Growth (YoY)	123.2%
EPS Growth (YoY)	21.8%
FCF Growth (YoY)	16.9%

Financial Health — source: SEC EDGAR
Altman Z-Score	4.51 (safe)

Valuation vs Sector & Industry
Stock P/E	-1.7
Sector P/E (Healthcare)	20.9
Industry P/E (Pharmaceutical Products)	17.0
vs Sector	-108.1%
vs Industry	-109.9%

Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional Holder	RA CAPITAL MANAGEMENT, L.P. ($38.24M)
Institutional Holders Tracked	10

Company
Sector	Healthcare
Industry	Pharmaceutical Products
CEO	Evert Schimmelpennink
Employees	6
Country	US
IPO Date	2024-03-22

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.